In 2013, healthcare moved towards access, transparency, investments, and spending. In 2014, Frost & Sullivan anticipates new launches to occur across the life sciences spectrum, from preventive medicine to treating complex diseases. This market insight touches upon major events that occurred in 2013 and how 2014 is expected to shape up, including future investments, regulatory changes, and new launches. Key companies to watch are highlighted, and strategic recommendations are provided.
The pharmaceutical/biotechnology industry is continuing to move away from the blockbuster model approach and towards the treatment of orphan diseases and personalized medicine.
Continued growth in personalized medicine and companion diagnostics will move beyond oncology and into areas such as virology, central nervous system, and cardiology.
While the number of new molecular entities (NMEs) continues to decline, the life sciences industry has made great progress in treating complex conditions and providing greater ease of use for patients (e.g., oral medicines for complex conditions such as hepatitis C and multiple sclerosis).
The industry is seeing increasing speed and intensity of product competition in the areas of generics and biosimilars, including the recent European launch of biosimilar monoclonal antibodies (mAbs).
It is becoming the norm worldwide for payments and reimbursements to be tied to quality of care.
Pharmaceutical companies continue to move beyond the pill. Big pharma companies are looking to adopt alternative business models beyond prescription treatments to support the entire continuum of care such as disease prevention and patient monitoring.
Table Of Contents
Frost and Sullivanâs 2014 Life Sciences Outlook Table of Contents
Executive Summary 3 2013âThe Year That Was 5 2013âThe Year That Saw Healthcare Moving Towards Access, Transparency, Investments, and Spending 6 Regulatory Transitions in 2013âContinuing Evolution 7 Accelerating Trends Make Their Mark Globally 8 What is to Come 9 Expected Future Investments 10 Shifting Strategies in the Global Marketplace 11 Life Sciencesâ2014 Outlook 12 New Launches Cross the Spectrum from Preventive to Complex 13 Life Science Companies To Watch in 2014 14 Frost and Sullivan Predictions for 2014 16 Legal Disclaimer 18 The Frost and Sullivan Story 19